AstraZeneca PLC released more pivotal test data for its Covid-19 vaccine, claiming that the bullet was 76% effective in inhibiting Covid-19 with symptoms in a more complete study of study results than it did. company previously provided.
AstraZeneca said its latest figures on vaccine efficacy were based on a study of 190 cases of symbolic Covid-19 in the trial, 49 more cases than the company had examined earlier.
Despite the additional issues, the performance of the vaccine was in line with what AstraZeneca had initially reported.
The drug dealer in London had set fire to it earlier in the week after providing preliminary data from the trial showing that the vaccine was 79% effective in 141 subjects.
An independent review board said the data was out of date, prompting the U.S. National Institute for Allergies and Infectious Diseases to issue an unusual statement raising experts’ concerns.